BioSpace News Archive

As a premier analytics solutions provider, Quantzig has helped leading businesses tackle the disruptions in the current business milieu. As a part of its continued efforts, Quantzig today announced the completion of its latest patient journey analysis engagement. During the course of this engagement, Quantzig successfully collaborated with a leading pharmaceu

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80 th American Diabe

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced that management will host a conference call and webcast on Tuesday, May 12, 2020, to discuss financial results for the first quarter ended March 31, 2020, and provide a corporate update.

Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it will report its financial results for the first quarter ended March 31, 2020, on Monday, May 11, before the market opens. Menlo will host a conference call and webcast at 8:30 a.m. Eastern Time on Monday, May 11 to di

Motus GI Holdings, Inc. announced that the U.S. Patent and Trademark Office has issued patent No. 10646108 titled “Ancillary vacuum module usable with an endoscope”, which protects the Company’s flagship product – the Pure-Vu® System.

Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent1 of patients at increased risk of receiving a less effective treatment

Received ~$2.52 million in aggregate CIR payments in 2020 CIR to be used to fund on-going MS1819 Phase 2 clinical studies in Europe

Stryker announced that its Board of Directors has declared a quarterly dividend of $0.575 per share payable on July 31, 2020 to shareholders of record at the close of business on June 30, 2020, representing an increase of approximately 11% versus the prior year and unchanged from the previous quarter.

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today it has enrolled 22 patients in

Insmed Incorporated announced that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public of $23.25 per share.